What Yanida Treats: Main Uses and Benefits

The primary role of Yanida is to provide symptomatic assistance. This approach is generally applied across therapeutic domains where short-term supportive symptom management is appropriate. The medicine is used across key areas to address distressing manifestations and supports general well-being during symptomatic phases.

---

Easing Acute Symptomatic Discomfort

This is relevant in clinical settings involving the sudden onset or intensification of uncomfortable symptoms. Yanida provides short-term supportive relief, which generally helps to ease the overall symptom burden during phases of heightened patient distress. This includes supporting the management of symptoms related to physical discomfort, symptoms that create noticeable physiological strain, and heightened physiological activity.

“Applied in scenarios where additional management of discomfort is required.”

---

Supporting Daily Stability During Fluctuations

Yanida is commonly used in conditions marked by episodic or fluctuating symptom patterns that can create noticeable interference with routine activities. By offering symptomatic assistance, it supports patients in coping more steadily and helps maintain a sense of stability when symptoms become more noticeable. This is applicable when symptoms cluster into patterns, or when conditions present with systemic or localized discomfort.

Quick Fact: Relevant for managing symptom clusters

---

Assisting Management of Clustered Symptom Patterns

The medicine is applicable when symptoms tend to cluster into specific patterns that require temporary assistance in stabilization. It provides supportive relief for symptom groups associated with physiological or emotional tension, assisting with the easing of discomfort and supports the patient during difficult episodes by easing distress.

Regulatory References

1. European Medicines Agency guidance on therapeutic indication wording

The eligibility for using Yanida (Valsartan) is strictly defined by regulatory authorities based on age, physiological status, and underlying medical conditions.

Populations Who Must Not Use Yanida (Contraindications)

• Pregnancy: Use is contraindicated during the second and third trimesters. Treatment must be discontinued immediately upon detection of pregnancy.
• Severe Organ Impairment: Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis are excluded from use.
• Allergy: Individuals with known mathbfhypersensitivity to valsartan or any component of the tablet.
• Specific Drug Combination: Patients with mathbfdiabetes mathbfmellitus who are also taking an mathbfaliskiren-containing medicine are mathbfcontraindicated.

Age-Related Eligibility

Age Group	Eligibility Status (Official)
Adults (18+ years)	Approved for all labeled uses.
Children (6 to 16 years)	Approved for mathbfhypertension only.
Children (under 6 years)	Use is mathbfnot mathbfrecommended (e.g., in infants under 1 year).
Pediatrics (<18 years)	mathbfNot mathbfrecommended for heart failure or recent heart attack.

Conditional or Restricted Use

Patients with mild to moderate liver impairment or severe renal impairment (e.g., Creatinine Clearance <30 mL/min) are typically subject to restricted use or may be mathbfnot mathbfrecommended due to limited data. Yanida is also mathbfnot mathbfrecommended for women who are breastfeeding.

Interactions with other medicines and products

Yanida (Valsartan) interactions are formally documented and categorized based on their effects on electrolyte balance and the body's cardiovascular regulatory system.

Contraindicated Combinations

Coadministration with Aliskiren is prohibited in patients with diabetes mellitus or those with moderate to severe renal impairment. This restriction reflects a risk classification tied to increased occurrences of hypotension, hyperkalemia, and worsening renal function.

Interactions Affecting Electrolyte and Renal Status

• Potassium-Raising Agents: Concomitant use with substances such as potassium supplements, salt substitutes containing potassium, or potassium-sparing diuretics may cause hyperkalemia due to additive pharmacodynamic effects.
• Non-Steroidal Anti-Inflammatory Agents (NSAIDs): Coadministration may result in an attenuation of the antihypertensive effect and an increased risk of renal function deterioration. This renal risk is specifically heightened in elderly, volume-depleted, or pre-existing renally compromised patients.

Drug Exposure and Toxicity

Concomitant use with Lithium is documented to cause a clinically significant increase in serum concentrations of the latter, raising the potential for lithium toxicity. Furthermore, official regulatory documents note that the systemic exposure of Valsartan itself is approximately doubled in patients with mild-to-moderate hepatic insufficiency.

How Yanida Works

Yanida operates through the precise modulation of key signaling pathways to influence heightened or atypical physiological signaling. Its mechanism of action is focused across distinct mechanistic domains to influence pathway activity towards a modified operational state within the targeted biological systems.

---

Receptor- and Enzyme-Mediated Signaling Modulation

This domain covers Yanida's primary action, which initiates or suppresses signaling sequences by engaging specific receptors or enzymes within the target cells. This modification of early molecular steps is crucial for shaping systemic physiological outcomes and restricts downstream signaling resulting from high mediator concentration.

---

Regulation of Overactive Pathway Cascades

Yanida is relevant in biological cascades where multiple layers of pathway activation and rapid response modulation occur. It engages mechanisms that influence feedback regulation and drives an alteration in physiological parameters that produces an alteration of heightened physiological responses.

How to Use Yanida: Official Administration Guidelines

Yanida is administered via the oral route and is available as a film-coated tablet in various strengths up to 320 mg. The primary administration instructions establish a long-term protocol defined by specific dose ranges and frequencies, rather than short-term use. The tablets must be swallowed whole with water, and may be administered with or without food, providing flexibility in the daily schedule.

Dosing regimens are specific to the management goal. For hypertension, the administration is typically once-daily, starting between 80 mg and 160 mg, with a maximum dose of 320 mg per day. In contrast, for heart failure or post-myocardial infarction treatment, the schedule requires a twice-daily regimen, starting lower (e.g., 20 mg or 40 mg twice daily) to allow for gradual dose adjustment.

This need for adjustment reflects the drug’s use in chronic therapy. The maximal antihypertensive effect is generally achieved after four weeks of initiating treatment, and dose increases, known as titration, must be separated by intervals of at least two to four weeks to allow for clinical assessment. For children aged 6 to 16, dosage is strictly calculated on a weight-based regimen. Official instructions note that no initial dose change is required for older adults or patients with mild to moderate kidney or liver impairment.

Research Evidence / Overview of Studies for Yanida

Yanida (Valsartan) was evaluated in various research settings to understand how it was studied for use in certain heart and circulatory conditions. The research is primarily based on Randomized Controlled Trials (RCTs), which compare the medicine against a placebo or another established therapy, as well as large-scale outcome trials that monitor patients over long periods.

---

Evidence for Managing Elevated Blood Pressure (Hypertension)

This section summarizes the structure of Randomized Controlled Trials (RCTs) and large long-term outcome trials that examined blood pressure measurement in cohorts taking Valsartan and studies also monitored major cardiovascular outcomes in those cohorts.

Research exploring the use of Valsartan for elevated blood pressure focused on measuring changes in Systolic and Diastolic Blood Pressure (BP). Long-term outcome studies, which sometimes lasted up to six years, reported measurements of BP differences between the study groups. Research in Pediatric patients (6 years and older) also examined the changes in blood pressure levels measured during the study period.

Regulators have noted the status of trials designed to explore patterns in major outcomes when Valsartan is used alone (monotherapy) in the general hypertensive population are not a primary part of the evidence base. Research observing long-term outcome patterns is often extrapolated from the overall evidence related to blood pressure lowering by the entire drug class.

---

Evidence for Heart Symptom and Strain Management

Studies in heart failure were conducted to determine the medicine's potential use in conditions characterized by functional limitations and periods of heightened symptom activity. Researchers studied the potential for Valsartan for outcomes monitoring physiological strain or stress, primarily by evaluating changes in the rate of hospitalization for heart failure and monitoring overall cardiovascular mortality.

Major clinical trials reported the incidence of heart failure hospitalizations and cardiovascular mortality across the compared groups. Findings were mixed when comparing outcomes for patients with heart failure who had a preserved ejection fraction versus those with a reduced ejection fraction. Research did not report an observable added measure of assistance when Valsartan was studied alongside established, full doses of an Angiotensin-Converting Enzyme (ACE) inhibitor.

---

What the Research Still Needs to Clarify

Comparative evidence is lacking for certain outcomes when Valsartan is used alone compared to placebo in high-risk patients. Also, the evidence for its use in managing Chronic Kidney Disease (Type 2 Diabetes-associated nephropathy) is still an area of research where data are still emerging, and certainty remains lower than for the primary heart indications.

Key Studies & References Valsartan Oral Tablet Official FDA Label (Current Version)

Common questions about Yanida (FAQ)

---

Q: Do the side effects of Yanida usually go away after taking it for a while?

Official documentation indicates that certain effects, such as symptomatic hypotension (low blood pressure), are more likely to occur when treatment is first initiated or during dose adjustments. This indicates that the occurrence of some effects may vary over the course of treatment, particularly after the initial period.

---

Q: Is Yanida safe for use in older adults (e.g., people over 65)?

Yanida is approved for all labeled uses in the adult population (18 years and older). Official instructions note that for older adults (e.g., those over 65) with normal or mild to moderate kidney or liver function, no change to the initial dose is generally required. The use of the medicine often requires the monitoring of kidney function and electrolytes.

---

Q: What happens if a person forgets to take a dose of Yanida?

Regulatory-based patient information suggests taking the missed dose as soon as the person remembers. However, if it is already close to the time for the next scheduled dose, the missed dose is typically skipped, and the person resumes the regular schedule. Taking extra or double doses is not advised.

---

Q: How long does Yanida stay in a person's system after the last dose?

The active ingredient in Yanida, Valsartan, reaches its peak concentration in the blood approximately two to four hours after a dose. The elimination profile of the active ingredient indicates it does not typically accumulate in the bloodstream with repeated daily dosing.

---

Q: Can Yanida be used by people who are pregnant or are planning to become pregnant?

Yanida is contraindicated (must not be used) during the second and third trimesters of pregnancy due to a critical risk of injury or death to the developing fetus. Official information emphasizes the importance of discussing medication use with a health professional before conception or discontinuing the drug immediately if pregnancy is confirmed.

---

Q: Can Yanida be taken with alcohol?

Official patient information describes that the use of the active ingredient with alcohol may be associated with an increased risk of certain side effects. Specifically, it can heighten feelings of dizziness or lightheadedness that are associated with the medicine lowering blood pressure.

---

Q: Are there any long-term health risks associated with taking Yanida for many years?

Regulatory bodies continuously monitor the drug supply for non-clinical risks. Regulatory bodies have addressed and monitored risks related to trace impurities found in the manufacturing process of the active ingredient, such as nitrosamines, which are monitored over a person's lifetime of exposure.

---

Q: Is it possible to take Yanida with common vitamin supplements like Vitamin D or multivitamins?

Official information advises patients to inform their health professional about all medicines and supplements being used, including over-the-counter medicines and vitamins. The drug label specifically warns against using supplements that are known to raise potassium levels, as this can interact with Yanida’s action.

---

Q: Can Yanida cause weight changes (gain or loss)?

While the active ingredient is not commonly linked to generalized weight gain or loss, its effects on the cardiovascular system may, in some patients, lead to fluid retention. This fluid retention can sometimes manifest as apparent weight gain or swelling in the arms and legs. Changes in fluid or weight should be discussed with a health professional.

---

Q: Is there a reason Yanida is usually taken at a specific time of day (e.g., morning or evening)?

Yanida is typically prescribed as a once-daily medicine and provides blood pressure control over a full 24-hour period. Studies have examined the effects of the active ingredient on blood pressure control and noted that the timing of administration, such as taking the dose at bedtime, may influence the nocturnal-diurnal blood pressure ratio (the difference in pressure between sleeping and waking hours).

---

Q: Can taking Yanida affect the results of common lab tests (e.g., blood sugar, cholesterol)?

The official labeling describes the importance of monitoring a person's renal function (kidney health) and potassium levels in susceptible patients, and these values are determined through lab testing. Other common labs, such as blood sugar or cholesterol, are not typically highlighted as being directly affected by the medicine’s core mechanism.

---

Q: Can Yanida be used in children or adolescents?

Yanida is formally approved for the treatment of hypertension (high blood pressure) in children and adolescents 6 to 16 years of age. It is not recommended for children younger than 6 years old, or for treating heart failure or recent heart attack in patients under 18 years of age.

---

Q: What is the typical time frame before a doctor evaluates whether Yanida is working?

Official administration guidelines for the high blood pressure indication state that the maximal antihypertensive effect is generally reached after about four weeks of initiating treatment. Dose adjustments, if necessary, are typically separated by intervals of two to four weeks to allow for a comprehensive clinical assessment of the medicine's effect.

---

Q: Can a person take Yanida if they have a known allergy to a different type of medicine?

Use of Yanida is contraindicated if a person has a known hypersensitivity (severe allergy) to the active ingredient, Valsartan, or any component of the tablet. Official information for Yanida focuses on the contraindication for a known hypersensitivity to its active ingredient.

---

Q: Why do doctors switch patients from an older drug to Yanida for the same condition?

Regulatory documents describe that the active ingredient, Valsartan, works by a different mechanism (blocking the Angiotensin II Receptor) than some older classes of blood pressure medicine, such as ACE inhibitors. This difference in action provides an alternative therapeutic pathway for patients, such as those who experience certain side effects from the older class of drugs.

---

Q: Are there any common lifestyle factors (e.g., smoking) that affect how Yanida works?

The product label frames blood pressure control as part of a comprehensive cardiovascular risk management plan. This management plan includes lifestyle factors such as smoking cessation and changes to diet and exercise, which are often discussed in the context of cardiovascular health and optimizing the overall treatment effect.

---

Q: Does Yanida affect a person's ability to drive or operate machinery?

Official patient information advises that Yanida may, in rare cases, cause side effects like dizziness and affect a person's ability to concentrate. It is generally advised that a person understands how the medicine affects them before engaging in activities that require full attention, like driving a vehicle or operating machinery.

---

Q: Are there any specific organs that Yanida has a warning for regarding potential impact?

Regulatory documents include specific warnings for several organs and systems. This includes warnings about the fetal system (critical risk in later pregnancy), the kidneys (risk of impairment), and the liver (contraindicated in severe impairment or disease).

Yanida (Valsartan) must be stored according to official regulatory labeling to ensure its stability.

Official Storage and Handling

Mandatory conditions: Store the oral tablets at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be kept in its original container and the container must remain tightly closed when not in use. It is a mandatory requirement to store the medicine out of the sight and reach of children to prevent accidental ingestion. Do not expose the tablets to freezing temperatures; do not freeze.

Disposal Instructions

Unused or expired Yanida should be disposed of by taking it to an authorized drug take-back program. If a take-back program is unavailable, the medicine may be secured in the household trash. It must be mixed with an undesirable substance, placed in a sealed bag, and discarded. Do not flush the tablets down the toilet or pour into any drain.